[go: up one dir, main page]

Iqbal et al., 2003 - Google Patents

Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays

Iqbal et al., 2003

View PDF
Document ID
808709672938188109
Author
Iqbal K
Alonso A
El-Akkad E
Gong C
Haque N
Khatoon S
Pei J
Tanimukai H
Tsujio I
Wang J
Inge G
Publication year
Publication venue
Journal of Molecular Neuroscience

External Links

Snippet

Neurofibrillary degeneration has primary and pivotal involvement in the pathogenesis of Alzheimer disease (AD) and other tauopathies. The inhibition of this lesion offers a promising therapeutic approach. The microtubule-associated protein (MAP) tau is …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Similar Documents

Publication Publication Date Title
Iqbal et al. Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays
Iqbal et al. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention
Pîrşcoveanu et al. Tau protein in neurodegenerative diseases-a review
Lee et al. Neurodegenerative tauopathies
Mandelkow et al. Biochemistry and cell biology of tau protein in neurofibrillary degeneration
Gong et al. Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer′ s disease: a therapeutic target
Lee Disruption of the cytoskeleton in Alzheimer's disease
Wang et al. The expression of calcium/calmodulin-dependent protein kinase II-α in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology
Iqbal et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion
Ho et al. Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role
US8367360B2 (en) Method of screening for inhibitors of tau protein phosphororylation by tyrosine kinase c-Abl
Taymans et al. Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
Watanabe et al. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer’s disease
Shanley et al. LRRK2 facilitates tau phosphorylation through strong interaction with tau and cdk5
US10016414B2 (en) Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
Iqbal et al. Developing pharmacological therapies for Alzheimer disease
Abdi et al. 14-3-3 proteins—a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer’s disease
Delobel et al. Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1
Iqbal et al. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration
Khalid et al. Alzheimer neurofibrillary degeneration
Iqbal et al. Pivotal role of neurofibrillary degeneration in Alzheimer disease and therapeutic targets
Montalto Study of a cyclic nucleotide-mediated mechanism that could favor an antiaggregant conformation of tau protein
Hark Pulse-Chase Proteomics of Alzheimer's Disease Models Reveals Synaptic Dysfunction Originates in Presynaptic Terminals
Kanungo et al. Deregulation of cytoskeletal protein phosphorylation and neurodegeneration
Fallacara et al. Inhibitors of tau-phosphorylating kinases